期刊文献+

万古霉素的药代动力学研究进展 被引量:29

Progress in pharmacokinetics of vancomycin
下载PDF
导出
摘要 万古霉素(多肽类抗生素)能有效治疗革兰阳性菌尤其是耐甲氧西林金葡菌和表皮葡萄球菌、肠球菌引起的感染,其特点是具有时间依赖性,峰浓度为25~40 mg·L^(-1),谷浓度5~15 mg·L^(-1);主要不良反应肾毒性的发生与过高的谷浓度有关。由于血液透析能清除部分药物,因此行高通量血液透析的患者,预防或治疗使用万古霉素时,要注意调整剂量。血药浓度测定、药代动力学参数的估算等方法,有助于临床医生制订个体化给药方案,减少或避免药物毒性。 Vancomycin is an effective glycopeptide antibiotics against a wide variety of gram positive bacteria and has been widely used in clinical practice especially in patients with methicillin - resistant Staphylococcus aureus (MRSA) infections. Its PK/PD profiles is time - dependent, ideal peak concentration is 25 -40 mg · L^- 1 and trough concentration is 5 - 15 mg · L^-1. Nephrotoxity is one of the major side effects and related to high trough levels. Vancomycin for the treatment or prophylaxis of patients undergoing high flux hemodialysis need for dose adjustments due to dialutie removal. Measurement of serum drug concentration, assessment pharmacokinetie parameters and other ways can help doctors in planning individualized regimens, which will minimize or avoid the occurrence of drug toxicity.
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2008年第6期529-532,共4页 The Chinese Journal of Clinical Pharmacology
关键词 万古霉素 药代动力学 治疗药物监测 vancomycin pharmacokinetics therapeutic drug monitoring
  • 相关文献

参考文献21

  • 1Rybak MJ . The pharmacokinetic and pharmacodynamic properties of vancomycin [ J ] . Clin Infect Dis, 2006 ;42 ( Suppl. ) : S35 -S39.
  • 2Laiprasert J, Klein K, Mueller BA, et al. Transplacental passage of vancomycin in noninfected term pregnant women [ J ]. Obstet Gynecol, 2007; 109:1105-1110.
  • 3de Jesu's Valle M J, Lo'pez FG, Hurle AD, et al. Pulmonary versus systemic delivery of antibiotics: comparison of vancomycin dispositions in the isolated rat lung [ J ]. Antimicrob Agents Chemother, 2007 ; 51 : 3771 - 3774.
  • 4Hyatt JM, McKinnon PS, Zimmer GS, et al. The importance of pharmacokinetic pharmacodynamic surrogate markers to outcome [J]. Clin Pharmacokinet, 1995 ;28 : 143 - 160.
  • 5Hermsen ED. Pharmacokinetic Training packet for Pharmacists [DB/OL]. http ://intranet. nebraskamed. com/careers/education/asp/pdfs/ pk - training packet, pdf. ,2007 - 09 - 12.
  • 6Duffull SB , Begg EJ, Chambers S T,et al. Efficacies of different van- comycin dosing regimens against Staphylococcus aureus determined with a dynamic in vitro model[ J ]. Antimicrob Agents Chemother, 1994 ; 38 : 2480 - 2482.
  • 7Jeffres MN , Isakow W, Doherty JA, et al. Predictors of mortality for methicillin - resistant Staphylococcus aureus health - care - associated Pneumonia: specific evaluation of vancomycin pharmacokinetic indices [ J ]. Chest, 2006 ; 130:947 - 955.
  • 8Wang JT, Fang CT, Chen YC. Necessity of a loading dose when using vancomycin in critically ill patients [ J ]. J Antimicrob Chemother, 2001 ;47 : 246.
  • 9Jeffres N , Isakow W, Doherty JA ,et al. A retrospective analysis of pos- sible renal toxicity associated with vancomycin in patients with health care - associated methicillin - resistant Staphylococcus aureus Pneumonia[J]. Clin Ther, 2007;29:1107 - 1115.
  • 10Lucksiri A, Scott MK, Mueller BA, et al. CAHP - 210 dialyzer influence on intra -dialytic vancomycin removal [ J ]. Nephrol Dial Transplant, 2002; 17:1649 - 1654.

同被引文献169

引证文献29

二级引证文献112

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部